Furthermore , this therapy could increase the dem and on radiation re sources .
There is no evidence on which to make a recommendation for patients with node-negative tumours that have not penetrated the muscularis propria .
For patients unable to undergo radiation , adjuvant chemotherapy alone may be of benefit , particularly for those with lymph-node metastases .
There is insufficient evidence from r and omized trials to recommend neoadjuvant chemotherapy , or neoadjuvant or adjuvant radiotherapy or immunotherapy , either alone or in combination , outside a clinical trial .
OBJECTIVE To make recommendations on the use of neoadjuvant or adjuvant therapy in addition to surgery in patients with resectable gastric cancer ( T1 - 4 , N1 - 2 , M0 ) .
OPTIONS Neoadjuvant or adjuvant treatments compared with " curative " surgery alone .
OUTCOMES Overall survival , disease-free survival , and adverse effects .
The radiation fields used can possibly damage the left kidney , result ing in hypertension and other renal problems .
Randomized clinical trial of adjuvant mitomycin plus tegafur in patients with resected stage III gastric cancer.
PURPOSE The efficacy of adjuvant chemotherapy in gastric cancer is controversial . We conducted a phase III , r and omized , multicentric clinical trial with the goal of assessing the efficacy of the combination of mitomycin plus tegafur in prolonging the disease-free survival and overall survival of patients with resected stage III gastric cancer . PATIENTS AND METHODS Patients with resected stage III gastric adenocarcinoma were r and omly assigned , using sealed envelopes , to receive either chemotherapy or no further treatment . Chemotherapy was started within 28 days after surgery according to the following schedule : mitomycin 20 mg/m(2 ) intravenously ( bolus ) at day 1 of chemotherapy ; 30 days later , oral tegafur at 400 mg bid daily for 3 months . Disease-free survival and overall survival were estimated using the Kaplan-Meier analysis and the Cox proportional hazards model . RESULTS Between January 1988 and September 1994 , 148 patients from 10 hospitals in Catalonia , Spain , were included in the study . The median follow-up period was 37 months . The tolerability of the treatment was excellent . The overall survival and disease-free survival were higher in the group of patients treated with chemotherapy ( P = .04 for survival and P = .01 for disease-free survival in the log-rank test ) . The overall 5-year survival rate and the 5-year disease-free survival rate were , respectively , 56 % and 51 % in the treatment group and 36 % and 31 % in the control group . CONCLUSION Our positive results are consistent with the results of recent studies ; which conclude that there is a potential benefit from adjuvant chemotherapy in resected gastric cancer
Furthermore , this therapy could increase the dem and on radiation re sources .
There is no evidence on which to make a recommendation for patients with node-negative tumours that have not penetrated the muscularis propria .
For patients unable to undergo radiation , adjuvant chemotherapy alone may be of benefit , particularly for those with lymph-node metastases .
There is insufficient evidence from r and omized trials to recommend neoadjuvant chemotherapy , or neoadjuvant or adjuvant radiotherapy or immunotherapy , either alone or in combination , outside a clinical trial .
OBJECTIVE To make recommendations on the use of neoadjuvant or adjuvant therapy in addition to surgery in patients with resectable gastric cancer ( T1 - 4 , N1 - 2 , M0 ) .
OPTIONS Neoadjuvant or adjuvant treatments compared with " curative " surgery alone .
OUTCOMES Overall survival , disease-free survival , and adverse effects .
The radiation fields used can possibly damage the left kidney , result ing in hypertension and other renal problems .